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Identity 
Other names: FLJ40431 
HGNC (Hugo): VAV3 
Location: 1p13.3 




The VAV3 gene is comprised of 27 exons spanning 
393.7 kb on chromosome 1p13.3. It is located on the 
reverse strand 108113782 bp from pter -108507545 
basepairs from pter. 
Transcription 
There are two known isoforms produced by alternative 
splicing and a third transcript thought to  
be derived from alternate promoter usage (Vav3.1). 
The alpha isoform is the canonical sequence and is 
derived from the full 27 exons. Isoform beta differs in 
the N terminus from the alpha isoform as follows: The 
residues 1-107 in the alpha isoform, 
MEPWKQCAQW...DLFDVRDFGK, are replaced by 
MQLPDCPCRAHLP in the beta isoform. The beta 
isoform is produced from a unique exon 1 spliced to 
exons 4-27 (Maier et al., 2005). Additionally, a 
transcript variant encoding only the C terminal SH3 
SH2 SH3 domains has been identified and is known as 
Vav3.1. This variant is derived from a unique exon 18 
and exons 19-27 (Maier et al., 2005) and is thought to 
be produced either by alternative splicing or through 
alternate promoter usage. The Vav3 mRNA consists of 
a 54 base pair 5 prime UTR and a 2171 basepair 3 
prime UTR (Trenkle et al., 2000). The promoter region 
of Vav3 contains predicted binding sites for the 
following transcription factors: STAT3, c-MYB, 
 
Figure 1. Upper figure shows gene organization for the alpha (canonical) isoform (ID NM 006113.4) and isoform 2 (ID NM 001079874.1) 
which corresponds to the 287 amino acid Vav3.1 transcript variant (described below). Lower panel illustrates neighboring genes. Figures 
adapted from NCBI Gene database. 
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LMO2, GATA-1, GCNF-2, E47, GCNF-1, PAX-5, 
POU2F1, and FOXO1A (information obtained from 
data deposited in Genecard database through use of 
SABiosciences' text mining application and the UCSC 
genome browser). It is worth mentioning that the gene 
locus is complex and could potentially produce up to 
13 different isoforms resulting from alternative splicing 
and alternate promoter usage (Thierry-Mieg and 
Thierry-Mieg, 2006). 
Vav3 can be modified posttranslationally by 
phosphorylation. Phosphorylation site prediction 
identifies phosphorylation sites at T131, S134, Y141, 
Y173, S511, T606 and Y797. Sites residing in the N 
terminal region have been shown to regulate activation 
of Vav3 GEF function (Movilla and Bustelo, 1999). In 
the unphosphorylated state, the GEF domain is 
prevented from physical association with Rho proteins 
by the Vav3 N terminal domains. These domains 
(calponin homology and acidic domains) form an 
autoinhibitory loop via intramolecular interactions. 
Vav3 is recruited via its SH2 domain to 
phosphotyrosine residues on interacting proteins, 
including activated growth factor receptors. Once 
bound to active growth factor receptors, or other 
molecules containing intrinsic tyrosine kinase activity, 
Vav3 becomes tyrosine phosphorylated (Movilla and 
Bustelo, 1999; Bustelo, 2002; Zugaza et al., 2002). 
Tyrosine phosphorylation of Vav3 results in a 
conformational change that relieves the autoinhibition, 
thus activating the GEF function by allowing access of 
Rho proteins to the GEF domain (Movilla and Bustelo, 
1999; Yu et al., 2010). Tyrosine 173 in particular is a 
critical residue in this process (Llorca et al., 2005; Yu 
et al., 2010). Consistent with an autoinhibitory role f 
the N terminal regions, removal of both the calponin 
homology and the acidic domains results in constitutive 
activation of Vav3 GEF function (Movilla and Bustelo, 
1999; Zeng et al., 2000; Zugaza et al., 2002). 
Protein 
 
Figure 2. Functional domains of Vav3 proteins and their relative 
positions. Abbreviations are as follows: CH: calponin homology, 
AD: acidic domain, DH: DBL homology, PH: pleckstrin 
homology, CRD: cysteine rich domain, SH3: Src homology 3 
and SH2: Src homology 2. 
Description 
The VAV3 gene encodes a 847 amino acid mature 
protein. The mature protein has a molecular mass of 
approximately 98 kDa and functions as a guanine 
nucleotide exchange factor (GEF) for members of the 
Rho family of small GTPases (Movilla and 
Bustelo,1999; Trenkle et al., 2000). Vav3 is structurally 
complex consisting of multiple functional domains. 
These domains consist sequentially of a single calponin 
homology domain encompassing residues 1-119, an 
acidic domain, a DBL homology domain which confers 
GEF function. The DBL homology domain is 
comprised of residues 192-371, followed by a 
pleckstrin homology domain, spanning residues 400-
502 a cysteine rich domain (also termed a zinc finger 
domain) comprising residues 513-562 and two SH3 
domains flanking a single SH2 domain. The SH3-SH2-
SH3 cassette comprises the C terminal portion of Vav3 
and extends from the N terminal SH3 domain (residues 
592-660), to the C terminal SH3 domain (residues 788-
847) and includes the intervening SH2 domain 
(residues 672-766) (Trenkle et al., 2000). Residing 
within the N terminal SH3 domain is a proline rich 
region which may be involved in facilitating 
intramolecular interactions between the C terminal 
regions (our unpublished observations). 
 
Figure 3. Schematic showing inactive (top panel) and active 
(bottom panel) conformations of Vav3. Movement of the N 
terminal regions to allow RhoGTPase access to the DH domain 
is regulated by phosphorylation events. 
Expression 
Vav3 is broadly expressed but with highest levels in 
cells of hematopoietic lineages (Trenkle et al., 2000). 
Localisation 
Vav3 is located predominantly in the cytoplasm, andis 
often recruited to the membrane upon activation of the 
various cell surface receptors that are coupled to Vav3 
phosphorylation (Zeng et al., 2000). 
Function 
Vav3 functions as a guanine nucleotide exchange factor 
mediating activation of Rho GTPases by stabilization 
of the nucleotide free state of Rho proteins. 
Specifically, Vav3 has been shown to act as a GEF for 
RhoA, RhoG and RAC1 (Movilla and Bustelo, 1999; 
Zugaza et al., 2002). Vav3 couples the activation of 
growth factor type receptors such as IGFR, EGFR, 
PDGFR, insulin receptor and ROS receptor (Zeng et 
al., 2000) to downstream signaling molecules including 
but not limited to Jun kinase, NFKappa B, MAPK and 
Stat pathways (Moores et al., 2000; Sachdev et al., 
2002). More recently, Vav3 activation by Eph 
Receptors has been demonstrated (Fang et al., 2008) 
and a large number of studies have shown the 
activation of Vav3 upon integrin signaling (Gakidis et 
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al., 2004; Faccio et al., 2005; Pearce et al., 2007; 
Sindrilaru et al., 2009). 
Vav3 is implicated in B cell induced antigen 
presentation to T cells (Malhotra et al., 2009) and 
mediates both B and T cell signaling events and 
alteration of macrophage morphology (Sindrilaru et al., 
2009). Additionally, protein interactions with the C
terminal SH3 SH2, SH3 cassette have revealed roles in 
scaffolding through adaptor like actions (Bustelo, 2001; 
Yabana and Shibuya, 2002).  
Additional functions of Vav3 in distinct tissues are 
listed below.  
Nervous system: NGF-induced neurite outgrowth in 
PC12 cells requires Vav3-mediated activation of Rac. 
This process involves P13K activation which occurs 
upstream of Vav3 (Aoki et al., 2005). Vav3 is also 
important for neuronal migration during development 
(Khodosevich et al., 2009). Additionally, Vav3 
knockout mice show defects in Purkinje cell dendrite 
branching, granule cell migration and survival. 
Functionally the animals show deficiencies in motor 
coordination and gaiting consistent with a role for Vav3 
in neuronal guidance, cerebellar development and 
function (Quevedo et al., 2010).  
Skeletal system: Studies in osteoclasts support a role 
for Vav3 in mediating proper bone deposition. 
Specifically, Vav3 deficient osteoclasts exhibit 
abnormalities in actin cytoskeletal rearrangements, cell 
spreading, and resorptive activities. Consistent with the 
actions of Vav3 on integrin signaling, the osteoclast 
defects were found to be due to impaired integrin 
engagement. Further, Vav3 deficient mice have 
increased bone density and are refractory to PTH-
mediated bone resorption (Faccio et al., 2005). 
Cardiovascular system: An important role for Vav3 in 
maintaining proper cardiovascular homeostasis was 
suggested by experiments performed in Vav3 null 
mice. These mice exhibited many symptoms of 
cardiovascular dysfunction including tachycardia, 
hypertension and cardiovascular remodeling. 
Consistent with these symptoms, the mice also 
exhibited a high degree of sympathetic tone including 
elevated circulating levels of catecholamines and renin-
angiotensin-aldosterone hyperactivity, resulting in
progressive loss of both cardiovascular and renal 
homeostasis (Sauzeau et al., 2006). 
Vascular smooth muscle: Vav3 is both necessary and 
sufficient for rat vascular smooth muscle cell 
proliferation. These effects occur through a Rac-1 
dependent mechanism, involving the effector Pak 1 
(Toumaniantz et al., 2010).  
Platelets: Consistent with a role for Vav3 in mediating 
integrin-based responses, Vav3 and Vav1 together are 
required for collagen exposure-mediated PLC 
activation in platelets. This signaling pathway occurs 
through the major platelet integrin alphaIIbbetaIII 
(Pearce et al., 2004). 
Angiogenesis: Mice deficient in both Vav3 and Vav2 
show reduced endothelial migration in response to the 
presence of tumor cells. Additionally Vav2 and Vav3 
were found to be necessary and sufficient for Eph A 
receptor-mediated angiogenesis both in vitro and in 
vivo (Hunter et al., 2006). 
Homology 
Vav3 is conserved among vertebrates including dog, 
cow, mouse, rat, chicken and zebrafish, and has been
shown to be present and conserved in Drosophila 
melanogaster (Movilla and Bustelo, 1999; Couceiro et 
al., 2005). Vav3 displays over 50% amino acid identity 
with other members of the Vav family of GEFS, Vav1 
and Vav2 which have a similar arrangement of 




None described. SNP analysis has revealed several 
genetic polymorphisms, the implications of which 
remain unclear. The single nucleotide polymorphisms 
resulting in differing amino acid sequence are as 
follows: residue 139, D to N, residue 298, T to S, 
residue 616 P to S, and residue Q to H. There are 
multiple SNPS residing in both the 3'UTR and 5'UTR 




Vav3 mRNA and protein are up-regulated during 
progression of human prostate cancer cells to androgen 
independence in cell culture and in vivo experimental 
studies (Lyons and Burnstein, 2006; Lyons et al., 
2008). Further, the importance of this upregulation t  
the disease process has been elucidated by more recent 
studies showing that Vav3 mRNA is up-regulated in 
prostate cancer tumor specimens obtained from men 
undergoing androgen deprivation therapy compared to 
levels in primary tumors (Holzbeierlein et al., 2004; 
Best et al., 2005; data deposited in public databases). 
Vav3 protein is overexpressed (relative to benign 
tissue) in almost one-third of prostate cancer tumor 
specimens (Dong et al., 2006).  
Additionally, Vav3 mRNA is up-regulated in androgen 
independent tumors in the Nkx3.1; Pten mouse model 
of prostate cancer (Banach-Petrosky et al., 2007; 
Ouyang et al., 2008) and targeted expression of a 
constitutively active form of Vav3 in prostate 
epithelium of transgenic mice leads to overactivity of 
the androgen receptor signaling axis and 
adenocarcinoma (Liu et al., 2008). Mechanistic studies 
show that Vav3 stimulates ligand independent 
androgen receptor activation by a GEF-dependent 
mechanism that requires the Rho GTPase, Rac 1 in 
prostate cancer cells (Lyons et al., 2008). Additionally, 
Vav3 enhances androgen receptor transcriptional 
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activity in the presence of low concentrations of 
androgen through a GEF independent pathway that 




Lee et al. reported that 81% of human breast cancer 
specimens exhibited higher levels of Vav3 compared to 
benign tissue (Lee et al., 2008). In addition, Vav3 
enhances the transcriptional activity of the estrogen 
receptor in a GEF dependent manner (Lee et al., 2008). 
Gastric cancer 
Note 
Downregulation of RUNX3, a member of the runt 
domain-containing family of transcription factors tha  
has tumor suppressive actions, has been implicated in 
promoting human gastric carcinogenesis. Silencing of 
RUNX3 expression via methylation was found in 75% 
of primary tumors and 100% of gastric metastasis. 
Stable reexpression of RUNX3 strongly inhibited 
peritoneal metastases. Further analysis suggested that 
Runx3 expression resulted in the downregulation of a 
number of genes including Vav3 thereby providing a 
potential line between Vav3 expression and gastric 
malignancy (Sakakura et al., 2005). 
Hepatocellular carcinoma 
Note 
Vav3.1 was down regulated in HepG2 cells in response 
to treatment with the hepatocellular carcinoma 
chemotherapeutic triterpenoid agent astragoloside. 
Downregulation of Vav3.1 was highly correlated with a 
decrease in malignant transformation, suggesting a role 
for Vav3.1 in the antitumor actions of astragoloside 
(Shen et al., 1997). 
Glioblastoma 
Note 
Vav3 is upregulated in glioblastoma as compared to 
nonneoplastic or lower grade gliomas. Down regulation 
of Vav3 by siRNA reduced glioblastoma invasion and 
migration. Further upregulation of Vav3 was shown to 
be an indicator of poor patient survival (Salhia et al., 
2008). 
Tumor growth and angiogenesis 
Note 
A role for Vav3 in promoting tumor growth and 
angiogensis has been revealed through studies using 
mice deficient in both Vav2 and Vav3 (Brantley-
Sieders et al., 2009). Vav2, Vav3 knockout mice 
transplanted with B16 melanoma or Lewis lung 
carcinoma cells showed decreases in tumor growth, 
tumor survival and neovascularization of tumors as 
compared to wild type control mice. The reduction in 
vascularization and tumor growth was found to be 
secondary to a reduction in endothelial cell migration 
(Brantley-Sieders et al., 2009). 
Type 1 diabetes mellitus 
Note 
Alteration in Vav3 expression may be an etiological 
factor in the development of beta islet cell destruction 
characteristic of type 1 diabetes (Fraser et al., 2010). 
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